ASCA Capitol Fly-In Success: 9 Legislators Sign On to ASC Quality & Access Act
The ASC Quality & Access Act is a major piece of legislation backed by ASCA and other ASC industry advocates. The Act was introduced to Congress in June 2013 and "amends title XVIII (Medicare) of the Social Security Act to require alignment of updates for ambulatory surgical center (ASC) services under a revised prospective payment system (PPS) with updates for hospital outpatient department services," according to the ASCA website.
After the Capitol Fly-In event, nine new cosponsors were added to the legislation. If passed, the bill would also establish a value-based purchasing program saving Medicare money — Medicare currently saves around $2.6 billion per year when procedures are done in the ASC instead of HOPD — and create a bonus pool for ASCs that meet quality standards. The ASC community would also have an appointee on the Advisory Panel on Hospital Outpatient Payment, according to ASCA.
The next Capitol Fly-In Program will be Sept. 9 to 10, giving participants the opportunity to learn more about issues impacting ASCs, the legislative process and advocacy for the industry. Last year, more than 130 ASC industry advocates participated in the Capitol Fly-In events and their efforts accounted for 90 percent of the ASC Quality & Access Act's cosponsors so far.
More Articles on Surgery Centers:
5 Observations on New ASC Physician Buy-In
9 ASCs With Total Hip Replacement Programs
36 Joint Venture ASC Administrators to Know
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- Drug-resistant tuberculosis alarms health officials — 4 notes
- Preventing & combating healthcare fraud: An ongoing process for ASCs
- Dr. Thomas Frieden talks opioids, antibiotic resistance & more with MedPage Today during final days at CDC
- Orphan drugs' annual average price tag cost $88.4k more than mainstream drugs in 2014: 4 key statistics
- GI leader to know: Dr. Robert Levine of the Boulder Medical Center